226 filings
Page 5 of 12
8-K
ne96i4ft jw2dflo4v
21 Apr 22
Regulation FD Disclosure
8:05am
8-K
l81k4i
11 Apr 22
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
4:30pm
424B5
pjmhlr8c2ogyoalzr8
29 Mar 22
Prospectus supplement for primary offering
4:20pm
S-8
g121ho3wk7f2cz8f4
29 Mar 22
Registration of securities for employees
4:15pm
8-K
o2ar9wcqwc85fceby7eg
29 Mar 22
Motus GI Reports Fourth Quarter and Full Year 2021 Financial Results
4:05pm
8-K
smpk8z49rvhzn
24 Feb 22
Motus GI Granted 180-Day Extension to Meet NASDAQ Minimum Bid Price Requirement
8:10am
8-K
0gavt7j598m5wn9am1mr
14 Feb 22
Motus GI Receives FDA Clearance to Market the Pure-Vu® EVS System
6:40am
8-K
lsz3e29
16 Dec 21
Motus GI Announces U.S. Patent For The Pure-Vu® System's Automatic Self-Purging Features
8:40am
8-K
ieq89ijl7l2cfxbirk8n
12 Nov 21
Motus GI Reports Third Quarter 2021 Financial Results and Provides Corporate Update
8:07am
8-K
8fxdg
26 Oct 21
Motus GI Announces Presentation of Results from Independent Study of Pure-Vu System in IBP Patients at the 2021 ACG Annual Scientific Meeting
8:12am
8-K
oquchmmpkxocf 63
8 Sep 21
Motus GI Announces Enrollment of Patients at Second Site in the European Union
8:16am
8-K
ntct5v73s7snj9c
27 Aug 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
y2gj3rk3ttgzk pk3
12 Aug 21
Motus GI Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:10pm
8-K
yxszos 6z9hvditmqiz1
21 Jul 21
Motus GI Secures Expanded $12M Credit Financing to Support Growth Strategy
8:06am
DEFA14A
pdtfxlvwesns fdihcug
2 Jul 21
Additional proxy soliciting materials
4:17pm